Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
SUMMARY: The emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS‐CoV) led to a rapid response not only to contain the outbreak but also to identify possible therapeutic interventions, including the generation of human monoclonal antibodies (hmAbs). hmAbs may be used therapeutically without the drawbacks of chimeric or animal Abs. Several different methods have been used to generate SARS‐CoV specific neutralizing hmAbs including the immunization of transgenic mice, cloning of small chain variable regions from naïve and convalescent patients, and the immortalization of convalescent B cells. Irrespective of the techniques used, the majority of hmAbs specifically reacted with the receptor binding domain (RBD) of the spike (S) protein and likely prevented receptor binding. However, several hmAbs that can bind to epitopes either within the RBD, located N terminal of the RBD or in the S2 domain, and neutralize the virus with or without inhibiting receptor binding have been identified. Therapeutic utility of hmAbs has been further elucidated through the identification of potential combinations of hmAbs that could neutralize viral variants including escape mutants selected using hmAbs. These results suggest that a cocktail of hmAbs that can bind to unique epitopes and have different mechanisms of action might be of clinical utility against SARS‐CoV infection, and indicate that a similar approach may be applied to treat other viral infections. Copyright © 2011 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peiris, J., Chu, C., Cheng, V., Chan, K., Hung, I., Poon, L., Law, K., Tang, B., Hon, T., Chan, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13412-5 · Cited by 2,375
Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, M. R., Murphy, B. R., Rappuoli, R., & Lanzavecchia, A. (2004) · Nature Medicine · doi:10.1038/nm1080 · Cited by 697 · cited 4×
“1 decreased viral titer in the lungs of infected mice, and group VI mAbs demonstrated protection against lethal challenge in a mouse model (Table 2) [69,81].”
BackgroundMethodInfluentialAntibodies, viruses and vaccines
Burton, D. R. (2002) · Nature Reviews Immunology · doi:10.1038/nri891 · Cited by 637
Wang, L.-F., Shi, Z., Zhang, S., Field, H., Daszak, P., & Eaton, B. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1212.060401 · Cited by 471 · cited 1×
“Bats serve as the reservoirs of group 1 and group 2 CoVs (SARS-CoV is classified in group 2b) [16,17,21].”
BackgroundHuman antibodies from transgenic animals.
Lonberg, N. (2005) · Nature Biotechnology · doi:10.1038/nbt1135 · Cited by 434
Olsen, C. W., Corapi, W. V., Ngichabe, C. K., Baines, J. D., & Scott, F. W. (1992) · Journal of Virology · doi:10.1128/jvi.66.2.956-965.1992 · Cited by 179
Rockx, B., Corti, D., Donaldson, E., Sheahan, T., Stadler, K., Lanzavecchia, A., & Baric, R. (2008) · Journal of Virology · doi:10.1128/jvi.02377-07 · Cited by 134 · cited 7×
“1 decreased viral titer in the lungs of infected mice, and group VI mAbs demonstrated protection against lethal challenge in a mouse model (Table 2) [69,81].”
BackgroundInfluentialA human SARS-CoV neutralizing antibody against epitope on S2 protein
Duan, J., Yan, X., Guo, X., Cao, W., Han, W., Qi, C., Feng, J., Yang, D., Gao, G., & Jin, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.089 · Cited by 114
Coughlin, M., Lou, G., Martinez, O., Masterman, S. K., Olsen, O. A., Moksa, A. A., Farzan, M., Babcook, J. S., & Prabhakar, B. S. (2007) · Virology · doi:10.1016/j.virol.2006.09.029 · Cited by 70
Self-citationAdaptation of SARS Coronavirus to Humans
Holmes, K. V. (2005) · Science · doi:10.1126/science.1118817 · Cited by 63
Cited by
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
(2020) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-200220-0773 · Cited by 486
CoV-AbDab: the coronavirus antibody database
Raybould, M. I. J., Kovaltsuk, A., Marks, C., & Deane, C. M. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa739 · Cited by 383
Yu, F., Du, L., Ojcius, D. M., Pan, C., & Jiang, S. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.01.003 · Cited by 366
Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2
Zhou, G., & Zhao, Q. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.45123 · Cited by 266
Metadata
- Authors
- Coughlin, M. M., & Prabhakar, B. S.
- Venue
- Reviews in Medical Virology
- Publisher
- Wiley
- Published
- 2011-09-08
- Volume
- 22
- Issue
- 1
- Pages
- 2-17
- ISSN
- 1052-9276 (ISSN-L)
- 1099-1654
- OpenAlex
- W2122089494
- Cited by
- 87
- References
- 10
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. https://app.cochat.ai/papers/10.1002/rmv.706
- The paper
- Coughlin, M. M., & Prabhakar, B. S. (2012). Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Reviews in Medical Virology. https://doi.org/10.1002/rmv.706
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.